After the positive impact of the virus Vaccination (Vaxinia) To test the cancer of the colon, breast, lung, ovary, and pancreas in animals for the first time, a human clinical trial is being conducted for the first time.
Scientists for the first time a dose of virus «Vaccination(Vaxinia) was injected into a cancer patient in a clinical trial to study how it works in his body. Vaccine with a scientific name «CF33-hNISIs also known as a virus.انکولتیکIt targets cancer tumor cells and helps treat cancer by shrinking them.
This type of treatment is referred to as «ImmunotherapyIt is known to cause cancerous tumors to shrink in early laboratory and animal experiments. Colon، سینه، Lung، Ovary And Pancreas Has been.
For more than a century, scientists have hoped to use this type of virus directly to kill cancer cells. This genetically modified virus not only infects and damages cancer cells, but also changes the cells, making them easier for the immune system to detect. Now the progress has been promising.
The vaccine virus was first developed by researchers at the US National Medical Center in California. The center, which is now in collaboration with «Imugene LimitedThe virus is evolving, and in recent years it has decided to look at the virus in a different way.
«Dong Lee“Immunotherapy is now showing its power in fighting tumors,” said the study’s lead author. “We believe the vaccine can shrink the tumor.”
Vaccination in the first stage of zinc testing 100 cancer patients Will be tested for metastatic and advanced solid tumors. These patients will receive the vaccine in two groups. The first group will use complementary drugs such as pembrolizumab along with the vaccine, and the other group will receive the virus alone.
Phase one trials only for safety testing and determination Appropriate dose It is for experimental treatment and is not performed with the aim of proving that this treatment is effective. In the next steps, the researchers intend to study how the body responds to the virus, its effect on the tumor, how it responds in combination with other drugs, and finally the patient’s health. This is expected Studies Up to years 2025 To finish.